Brooks Laboratories Limited (IN:BROOKS)
:BROOKS
Want to see IN:BROOKS full AI Analyst Report?
Top Page
Brooks Laboratories Limited
(BROOKS)
Select Model
Select Model
Rating:65Neutral
Price Target:
₹83.00
▼(-32.88% Downside)
Action:Reiterated
Date:06/02/26
The score is driven primarily by improved financial health (profitability turnaround and low leverage) tempered by a sharp FY2026 revenue decline and still-weak cash conversion. Technically, momentum is positive but extended and still below the 200-day trend. Valuation is supportive with a low P/E.
Positive Factors
Conservative balance sheet
Very low leverage (debt-to-equity ~0.07) and a growing equity base provide durable financial flexibility. This reduces default risk, supports capital allocation for R&D or products, and gives the company room to absorb shocks or pursue opportunistic investments over the next several quarters.
Negative Factors
Sharp revenue decline
A ~23% drop in top-line in FY2026 materially weighs on scale and the durability of the earnings rebound. Sustained revenue weakness can erode pricing power, increase per-unit costs, and make margins more sensitive to any further demand softness or loss of key customers over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage (debt-to-equity ~0.07) and a growing equity base provide durable financial flexibility. This reduces default risk, supports capital allocation for R&D or products, and gives the company room to absorb shocks or pursue opportunistic investments over the next several quarters.
Read all positive factors
Brooks Laboratories Limited (BROOKS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹2.19B
Dividend YieldN/A
Average Volume (3M)2.20K
Price to Earnings (P/E)9.2
Beta (1Y)1.65
Revenue Growth3.85%
EPS GrowthN/A
CountryIN
Employees293
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)3.97
Shares Outstanding29,457,249
10 Day Avg. Volume1,280
30 Day Avg. Volume2,199
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.89
Price to Sales (P/S)1.27
P/FCF Ratio21.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Brooks Laboratories Limited Business Overview & Revenue Model
Company Description
Brooks Laboratories Limited is a pharmaceutical enterprise engaged in the contractual manufacturing and distribution of medicinal products. The company serves both the Indian domestic market and international clients. Its comprehensive product por...
How the Company Makes Money
null...
Brooks Laboratories Limited Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
78
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.11B | 857.38M | 825.57M | 794.86M | 624.80M | 911.85M |
| Gross Profit | 364.78M | 179.65M | 139.22M | 225.13M | 126.02M | -79.11M |
| EBITDA | 177.76M | 70.60M | 58.22M | 41.73M | -291.68M | -134.50M |
| Net Income | 115.32M | 245.84M | -99.67M | -195.92M | -209.00M | -193.13M |
Balance Sheet | ||||||
| Total Assets | 1.40B | 1.48B | 1.24B | 904.45M | 1.10B | 1.96B |
| Cash, Cash Equivalents and Short-Term Investments | 18.03M | 75.49M | 12.48M | 1.25M | 232.00K | 26.05M |
| Total Debt | 78.33M | 85.17M | 75.83M | 56.42M | 65.12M | 252.59M |
| Total Liabilities | 242.82M | 255.17M | 255.90M | 248.60M | 356.44M | 615.91M |
| Stockholders Equity | 1.16B | 1.23B | 981.04M | 655.85M | 739.53M | 874.90M |
Cash Flow | ||||||
| Free Cash Flow | -3.84M | 50.87M | -971.00K | -101.20M | -149.58M | -650.53M |
| Operating Cash Flow | 3.19M | 85.92M | 17.62M | -96.81M | -144.91M | -374.41M |
| Investing Cash Flow | -1.03M | -29.82M | -460.41M | 1.82M | 4.95M | -249.09M |
| Financing Cash Flow | -2.30M | 9.34M | 441.96M | 96.01M | 114.14M | 640.71M |
Brooks Laboratories Limited Technical Analysis
Positive
123.65
Price Trends
61.59
Positive
62.39
Positive
86.10
Negative
Market Momentum
3.65
Negative
74.98
Negative
97.22
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BROOKS, the sentiment is Positive. The current price of 123.65 is above the 20-day moving average (MA) of 67.54, above the 50-day MA of 61.59, and above the 200-day MA of 86.10, indicating a neutral trend. The MACD of 3.65 indicates Negative momentum. The RSI at 74.98 is Negative, neither overbought nor oversold. The STOCH value of 97.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BROOKS.
Brooks Laboratories Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | ₹2.19B | 9.20 | ― | ― | 3.85% | ― | |
62 Neutral | ₹3.48B | 25.82 | ― | ― | 36.73% | 30.29% | |
60 Neutral | ₹6.52B | 107.45 | ― | ― | -1.22% | -52.32% | |
55 Neutral | ₹4.10B | -271.07 | ― | 0.66% | -3.52% | -108.70% | |
55 Neutral | ₹3.27B | 30.07 | ― | 0.26% | 21.67% | 23.11% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | ₹2.24B | -0.86 | ― | ― | -82.81% | -164.57% |
* Healthcare Sector Average
IN:BROOKS
Brooks Laboratories Limited
76.97
-73.03
-48.69%
IN:ALBERTDAVD
Albert David Ltd
710.30
-128.90
-15.36%
IN:MEDICAMEQ
Medicamen Biotech Limited
229.65
-193.08
-45.67%
IN:MEDICO
Medico Remedies Ltd.
41.04
-7.96
-16.24%
IN:NECLIFE
Nectar Lifesciences Ltd.
11.68
-10.89
-48.25%
IN:ZIMLAB
Zim Laboratories Ltd.
127.75
15.32
13.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.